|Application ||WB, IHC-P, IF, ICC|
|Predicted||Human, Mouse, Rat, Zebrafish|
|Calculated MW||34615 Da|
|Dilution||ICC (1:100 - 1:500), IF, IHC-P (1:100), WB (1:500 - 1:1000)|
|Other Names||SIAH2, HSiah2, Seven in absentia homolog 2, Siah-2|
|Target/Specificity||Recognizes endogenous levels of SIAH2 protein.|
|Reconstitution & Storage||Immunoaffinity purified|
|Precautions||Anti-SIAH2 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin- conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Mediates E3 ubiquitin ligase activity either through direct binding to substrates or by functioning as the essential RING domain subunit of larger E3 complexes. Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (POU2AF1, PML, NCOR1), a cell surface receptor (DCC), an antiapoptotic protein (BAG1), and a protein involved in synaptic vesicle function in neurons (SYP). Mediates ubiquitination and proteasomal degradation of DYRK2 in response to hypoxia. It is thereby involved in apoptosis, tumor suppression, cell cycle, transcription and signaling processes. Has some overlapping function with SIAH1. Triggers the ubiquitin-mediated degradation of TRAF2, whereas SIAH1 does not. Promotes monoubiquitination of SNCA.|
|Cellular Location||Cytoplasm. Nucleus. Note=Predominantly cytoplasmic. Partially nuclear|
|Tissue Location||Widely expressed at low level.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.